31 related articles for article (PubMed ID: 37321973)
1. Approaches to assessing 3β-hydroxysteroid dehydrogenase-1.
Alyamani M; McManus J; Patel M; Sharifi N
Methods Enzymol; 2023; 689():89-119. PubMed ID: 37802584
[TBL] [Abstract][Full Text] [Related]
2. Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer.
Zhang X; Wang Z; Huang S; He D; Yan W; Zhuang Q; Wang Z; Wang C; Tan Q; Liu Z; Yang T; Liu Y; Ren R; Li J; Butler W; Tang H; Wei GH; Li X; Wu D; Li Z
J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 38099500
[TBL] [Abstract][Full Text] [Related]
3. AKR1C3 Converts Castrate and Post-Abiraterone DHEA-S into Testosterone to Stimulate Growth of Prostate Cancer Cells via 5-Androstene-3β,17β-Diol.
Detlefsen AJ; Mesaros CA; Duan L; Penning TM
Cancer Res Commun; 2023 Sep; 3(9):1888-1898. PubMed ID: 37772993
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
5. 3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer.
Evaul K; Li R; Papari-Zareei M; Auchus RJ; Sharifi N
Endocrinology; 2010 Aug; 151(8):3514-20. PubMed ID: 20534728
[TBL] [Abstract][Full Text] [Related]
6. Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate Cancer Cells.
Moon HH; Clines KL; O'Day PJ; Al-Barghouthi BM; Farber EA; Farber CR; Auchus RJ; Clines GA
J Bone Miner Res; 2021 Aug; 36(8):1566-1579. PubMed ID: 33900658
[TBL] [Abstract][Full Text] [Related]
7. TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?
Piao YS; Wiesenfeld P; Sprando R; Arnold JT
J Steroid Biochem Mol Biol; 2013 Nov; 138():206-13. PubMed ID: 23770322
[TBL] [Abstract][Full Text] [Related]
8. 11β-hydroxyandrostenedione, the product of androstenedione metabolism in the adrenal, is metabolized in LNCaP cells by 5α-reductase yielding 11β-hydroxy-5α-androstanedione.
Swart AC; Schloms L; Storbeck KH; Bloem LM; Toit Td; Quanson JL; Rainey WE; Swart P
J Steroid Biochem Mol Biol; 2013 Nov; 138():132-42. PubMed ID: 23685396
[TBL] [Abstract][Full Text] [Related]
9. 3βHSD activity saturates at physiological substrate concentrations in intact cells.
McManus JM; Chung YM; Sharifi N
Prostate; 2023 Sep; 83(13):1306-1309. PubMed ID: 37321973
[TBL] [Abstract][Full Text] [Related]
10. Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics.
Naelitz BD; Sharifi N
Trends Endocrinol Metab; 2020 Sep; 31(9):680-690. PubMed ID: 32565196
[TBL] [Abstract][Full Text] [Related]
11. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
12. The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer.
Tamae D; Mostaghel E; Montgomery B; Nelson PS; Balk SP; Kantoff PW; Taplin ME; Penning TM
Chem Biol Interact; 2015 Jun; 234():332-8. PubMed ID: 25514466
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
